Health Encyclopedia

Bitolterol

Bitolterol Uses, Dosage, Side Effects & Interactions

Introduction to Bitolterol

Bitolterol is a short-acting bronchodilator medication used for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As a β2 adrenergic receptor agonist, bitolterol works by dilating the airways to relieve symptoms of bronchospasm, wheezing, and shortness of breath. This article provides a comprehensive overview of bitolterol, including its uses, dosage, side effects, and drug interactions.

Uses of Bitolterol

The primary therapeutic use of bitolterol is for the symptomatic relief of asthma and COPD. It acts as a bronchodilator, relaxing and widening the air passages in the lungs to make breathing easier. Bitolterol is particularly useful for managing acute exacerbations and providing short-term control of symptoms. Studies have shown its efficacy in improving lung function and reducing the frequency and severity of asthma attacks.

Mechanism of Action

Bitolterol is a pro-drug that is hydrolyzed by tissue esterases to its active form, colterol. As a β2 adrenergic receptor agonist, colterol binds to and activates β2 receptors in the airways, leading to relaxation of bronchial smooth muscle and dilation of the airways. This mechanism of action helps to counteract the bronchospasm and inflammation associated with asthma and COPD. Bitolterol’s pro-drug nature allows for a more localized effect in the lungs while minimizing systemic side effects.

Medical Indications

Bitolterol is indicated for the treatment of asthma and COPD in both adults and children. It is particularly useful for managing acute symptoms and providing quick relief during exacerbations. Compared to other short-acting bronchodilators like albuterol ( Ventolin), bitolterol may offer a slightly longer duration of action. However, it is important to note that bitolterol is not a replacement for long-term control medications and should be used in conjunction with anti-inflammatory drugs and other maintenance therapies as prescribed by a healthcare provider.

Dosage and Administration

Bitolterol is typically administered via inhalation using a metered-dose inhaler. The usual adult dose is 2 inhalations (370 mcg per inhalation) every 4 to 6 hours as needed, not to exceed 12 inhalations in 24 hours. For children aged 12 and above, the dosage is the same as for adults. Dosage adjustments may be necessary based on individual response and the severity of the condition. It is crucial to follow the dosing instructions provided by the prescribing doctor and not exceed the recommended maximum dose.

Pharmacokinetics and Pharmacodynamics

After inhalation, bitolterol is rapidly absorbed into the lungs, where it is hydrolyzed to its active form, colterol. The onset of action is typically within 5 to 15 minutes, with peak effects occurring within 1 to 2 hours. The duration of action is approximately 3 to 6 hours, which is slightly longer than some other short-acting bronchodilators. Colterol is metabolized in the liver and excreted primarily in the urine, with a small amount eliminated in the feces. The pharmacodynamic effects of bitolterol are mediated through its activation of β2 adrenergic receptors, leading to bronchodilation and symptom relief.

Side Effects and Adverse Reactions

Common side effects of bitolterol include tremors, nervousness, headache, lightheadedness, dizziness, and paresthesia. These side effects are generally mild and transient, often resolving with continued use. Rare but more serious side effects may include tachycardia, palpitations, hypertension, and hypokalemia. Long-term use of high doses may lead to tolerance and decreased effectiveness. It is important to report any severe or persistent side effects to a healthcare provider promptly.

Drug Interactions

Bitolterol may interact with certain medications, including other bronchodilators, beta-blockers, diuretics, and monoamine oxidase inhibitors (MAOIs). Concurrent use of bitolterol with other sympathomimetic agents may lead to additive side effects and increased risk of adverse reactions. Beta-blockers may counteract the bronchodilatory effects of bitolterol and should generally be avoided. Diuretics, especially potassium-depleting diuretics, may increase the risk of hypokalemia when used with bitolterol. MAOIs can potentiate the effects of bitolterol and increase the risk of severe hypertension.

Warnings and Precautions

Bitolterol should be used with caution in patients with cardiovascular disorders, hypertension, hyperthyroidism, diabetes, and seizure disorders. It may cause paradoxical bronchospasm, which can be life-threatening, and immediate discontinuation is necessary if this occurs. Bitolterol is not recommended for use during pregnancy unless the potential benefits outweigh the risks. It should also be used with caution in nursing mothers as it may be excreted in breast milk.

Use During Pregnancy and Lactation

The safety of bitolterol during pregnancy has not been established. Animal studies have shown some adverse effects on fetal development, but there are no adequate and well-controlled studies in pregnant women. Bitolterol should only be used during pregnancy if the potential benefits justify the potential risks to the fetus. According to the Drugs and Lactation Database (LactMed), it is not known if bitolterol is excreted in human milk. Caution should be exercised when administering bitolterol to nursing mothers, and the potential risks and benefits should be carefully considered.

Regulatory Status and Market Availability

Bitolterol was previously marketed in the United States under the brand name Tornalate. However, it is no longer actively marketed or commercially available in the US. The exact reasons for its discontinuation are not clearly established in the published literature. The regulatory history and approval status of bitolterol may vary in different countries, and it is important to consult local regulatory authorities for the most up-to-date information on its availability and approved indications.

Bitolterol